Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 8 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $34.00 (179.26% upside)

Current Analysts' Coverage Summary for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetDetailsShare
1/22/2015RBC CapitalInitiated CoverageSector Perform$15.00ViewTweet This Rating  Share This Rating on StockTwits
1/20/2015WedbushDowngradeOutperform -> Neutral$16.00ViewTweet This Rating  Share This Rating on StockTwits
1/15/2015Cowen and CompanySet Price TargetBuy$19.00ViewTweet This Rating  Share This Rating on StockTwits
1/15/2015WBB SecuritiesReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
1/8/2015Canaccord GenuityInitiated CoverageHoldViewTweet This Rating  Share This Rating on StockTwits
1/7/2015Roth CapitalSet Price TargetBuy$22.00ViewTweet This Rating  Share This Rating on StockTwits
11/11/2014ZacksReiterated RatingNeutral -> Neutral$17.00ViewTweet This Rating  Share This Rating on StockTwits
10/31/2014Robert W. BairdReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldViewTweet This Rating  Share This Rating on StockTwits
10/27/2014JMP SecuritiesDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
10/7/2014Credit SuisseReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
7/31/2014OppenheimerInitiated CoverageOutperform$45.00ViewTweet This Rating  Share This Rating on StockTwits
7/30/2014Deutsche BankReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
7/22/2014Bank of AmericaInitiated CoverageNeutral$27.00ViewTweet This Rating  Share This Rating on StockTwits
4/22/2014Citigroup Inc.UpgradeSell -> NeutralViewTweet This Rating  Share This Rating on StockTwits
4/21/2014Needham & Company LLCReiterated RatingBuy$36.00 -> $52.00ViewTweet This Rating  Share This Rating on StockTwits
4/21/2014William BlairUpgradeMarket Perform -> Outperform$63.00ViewTweet This Rating  Share This Rating on StockTwits
4/14/2014SidotiInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
12/23/2013Piper JaffrayUpgradeUnderweight -> Neutral$19.55 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013Leerink SwannLower Price TargetMarket Perform$44.00 -> $17.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013FBR Capital MarketsLower Price TargetMarket Perform$48.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013Janney Montgomery ScottDowngradeNeutral -> SellViewTweet This Rating  Share This Rating on StockTwits
10/30/2013FBR & CoInitiated CoverageMarket PerformViewTweet This Rating  Share This Rating on StockTwits
7/24/2013Burrill Institutional ResearchDowngradeOutperform -> Market Perform$39.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 1/25/2013 forward)